Risks: Cardiovascular

The Tools Got Fancier. The Fundamentals Didn't.

Cardiovascular disease is still the number one killer of men and women, in this country and globally. The major levers haven't changed in decades: hypertension, hyperglycemia, and hyperlipidemia. Add two things we don't have a clean number for — stress, which feeds all three, and the body's tendency to clot — and you've more or less described what's going to land most people in a cardiology office.

In 2026 the guidelines for two of those three got stricter. The lipid rules tightened in March. Blood pressure management keeps trending more aggressive. The calculators got more sophisticated. And yet, when you read the fine print, the things that actually drive your cardiovascular risk are exactly what they've always been. The odd part is what didn't move. Glucose targets at the population level are basically unchanged. We're getting more aggressive on cholesterol and blood pressure and leaving sugar where it sits.

That's the story I want to walk through. New math, old fundamentals.

The Lipid Guideline Got Stricter

The 2018 cholesterol guideline is gone. The American College of Cardiology and American Heart Association Joint Committee replaced it wholesale and published the new version in Circulation. The title change tells you the philosophy: it used to be the Management of Blood Cholesterol, and now it's the Management of Dyslipidemia. That's not cosmetic. It's a deliberate widening of the lens beyond LDL-C to include ApoB and lipoprotein(a).

The headline practice change is universal Lp(a) testing — measure it at least once in every adult. The paper reiterates that Lp(a) is strongly genetic. I'll grant that's the consensus, and then I'll offer what I actually see in clinic. I've watched this number swing by as much as 80% in individual patients, which makes me skeptical that genetics is the whole story. When someone's metabolic health improves meaningfully, I tend to see Lp(a) come down with it. My working interpretation is that a good chunk of what we're measuring tracks an underlying inflammatory state, not just an inherited set point. That's a heterodox read. I'm holding it loosely. But the data in front of me keeps suggesting it.

A Better Calculator, Same Inputs

Risk now runs through the PREVENT equation, and it's a genuine upgrade. It estimates two timelines — a 10-year and a 30-year risk — starting at age 30, which is the part I like most, because it forces the long view in younger patients.

Look at what it runs on, though. Smoking status, systolic blood pressure, cholesterol, whether you're already on a statin or blood pressure medication, diabetes, and kidney function, with age, sex, and body weight folded in. You can enhance it with hemoglobin A1c, a urine albumin-to-creatinine ratio, and a social deprivation index pulled from your zip code.

Here's what I found genuinely interesting. Adding those three enhancements — blood sugar, kidney protein, and social deprivation — barely moved the score. We treat those exact factors as the heavy hitters in long-term health. The model says that once you already know the basics, they add surprisingly little. Take that for what it's worth, but it's a useful reminder that the foundational variables are doing almost all the work.

The thresholds did move, and in the more-aggressive direction. The old rule was to start lipid-lowering therapy at a 10-year risk above 7.5%. That's been lowered to above 5%, with a note to consider starting therapy in the 3-to-5% range. More people, sooner.

So the calculator is fancier. The inputs are the same ones your grandmother's doctor cared about. Age, blood pressure, lipids, smoking, diabetes, kidney function, body weight. That's the whole ballgame, and it always has been.

Why Family History Didn't Make the Cut

One thing surprised me on first read: family history of cardiovascular disease isn't in the equation. That feels like an omission until you think about why. Hypertension, high cholesterol, elevated BMI, smoking patterns, and diabetes all cluster in families. By the time you've measured those, you've already captured most of what a family history was telling you. Family history didn't get cut because it doesn't matter. It got cut because the risk factors already smuggle it in.

Calcium Scores Finally Made the Cut

Cardiovascular imaging earned a real seat at the table, which is new. Historically there was no guideline recommendation tied to a coronary artery calcium score. The CAC scan is a cash-pay test that runs around $100 and measures calcification in the arteries. The new guidance treats any score above zero as a reason to act.

The early-intervention crowd pushes this further and argues for much lower lipid goals. The logic is that if you drive ApoB down into the 20-to-40 range — roughly neonatal levels — you can essentially stall the development of atherosclerosis before it starts. I think that's a defensible bet. I also think it's exactly the kind of bet that gets oversold, which brings me to the variable nobody puts on a lab slip.

The Real Variable Is Time

This is the number that should change how you think about all of it.

A lifelong reduction in LDL of about 10 mg/dL — the kind you inherit from a lucky genetic variant — is associated with a 16-to-18% reduction in cardiovascular events. A statin that drops LDL by roughly 39 mg/dL over four or five years buys you about a 22% reduction. Line those up per unit of cholesterol and the lifelong, low-dose exposure is three to four times more efficient than the aggressive, late one. Starting lower and earlier gets you a comparable long-term result to starting hard and late.

Sit with that, because it cuts against the instinct the new guidelines will create. My concern is that people read "stricter" and reach for high-intensity therapy in their fifties and sixties, when the real leverage was available decades earlier and for free. The things that lower lipids by meaningful amounts include the unglamorous stuff — a lifetime of high fiber intake plausibly delivers a risk reduction in the same neighborhood as a statin you started at 55.

Some of that is extrapolation. I think it matters anyway. The earlier you get into whole foods and regular movement, the better the math works out, and the math compounds the same way money does — little and often over a very long horizon.

Diabetes: The 2026 ADA Standards

The diabetes side updated in December 2025, and it's a living document now, revised throughout the year. A few things stood out.

GLP-1 medications are now recommended for adults with type 1 diabetes who carry an obese BMI — a real shift, since these drugs lived on the type 2 side for a long time. They're also moving toward the front line for liver disease: in type 2 patients with metabolic dysfunction-associated steatotic liver disease, or MASLD, a GLP-1 with proven liver benefit is now a preferred glucose-lowering choice. And continuous glucose monitors are no longer reserved for insulin users — the 2026 update recommends them well beyond that group, including for type 2 patients on any drug that can cause a low and, more broadly, anyone for whom the data improves management.

Underneath the technology, the basics held. A 5-to-7% weight loss goal to improve blood sugar and cut cardiovascular risk. Mediterranean and lower-carbohydrate eating patterns singled out as having the best current evidence for preventing or delaying type 2 diabetes. Same foundation, dressed in newer tools.

This is also where the three guidelines converge. PREVENT is now the common spine across lipids, blood pressure, and diabetes, all of them trying to account for the whole picture — cardiovascular, kidney, and metabolic — at once. And all of them front-load lifestyle before pharmacology. On paper, anyway. In clinic, I rarely see lifestyle given the runway it's owed before the prescription pad comes out.

Blood Pressure: The 2025 Update

Hypertension targets have moved more than once in my relatively short career. After the eighth Joint National Committee guidelines came out less stringent than the seventh, the AHA and ACC eventually went the other way and tightened the definition. Today hypertension is a blood pressure above 130/80. Not long ago the bar sat at 140/90, and it keeps creeping down.

The decision to start medication now runs through the same risk calculator paired with an elevated reading, and out-of-office blood pressure checks are recommended to guide what happens next. Same pattern as the lipid guideline: a smarter risk tool, a lower threshold, a push to treat earlier.

What I Actually Do in Clinic

I'll be honest about my bias. I've historically been slow to reach for medication in cardiovascular disease, because nearly all of these conditions have substantial non-pharmaceutical levers that come first. Dean Ornish built a career publishing on lifestyle changes outperforming a lot of what comes in a bottle.

The thing that keeps me up is the variable I can't quantify: stress. I've watched patients do everything right on paper — clean labs, good habits — and still have major cardiac events, often the same perfectionists whose discipline is itself a source of chronic stress. I've had several of these cases in recent years, and they've genuinely made me reconsider whether my reluctance to medicate was always the right call. As we age, cardiovascular risk becomes the number one driver of cancer, heart disease, and death all at once. That deserves humility in both directions.

So is hindsight 20/20? Would earlier pharmaceutical therapy have prevented or softened those outcomes? The honest answer is I don't know. What I do believe is that the newer guidelines, by lowering thresholds, at least let us intervene with smaller doses earlier rather than big hammers late.

What I'd want before going all-in is an honest accounting of the trade-off. I'm not a fan of the word "safe" attached to any intervention. Side effects are uncommon, and for the person who gets one, "uncommon" is no comfort at all. By one widely cited Johns Hopkins estimate, medical error ranks third among causes of death in this country. That's not an argument against treatment. It's an argument against the "set it and forget it" reflex, where we stack medications and supplements over the years and never circle back to ask whether each one is still earning its place.

So here's the framework I actually use. Start with lifestyle. Monitor labs, vitals, and affordable diagnostics over time. If the markers are improving, I stay out of the way. If they're worsening, repeatedly, and not responding to the basics, then we have an honest conversation about adding something — nutraceutical or pharmaceutical — to head off early disease. Lifestyle first. Measurement always. Escalation when the data, not the calendar, calls for it.

The guidelines got stricter. The fundamentals didn't change. Maintaining a healthy weight, eating real food, and moving your body — measured early and measured often — is still the foundation everything else is built on. The fancy tools just tell you, with more decimal places, what we already knew.

3-Point Summary

• The calculators got more sophisticated; the inputs didn't. The 2026 lipid guideline lowered the treatment threshold and adopted the PREVENT equation, but the variables that drive risk are the same ones we've tracked for decades — age, blood pressure, lipids, smoking, diabetes, kidney function, and body weight. Even the "enhanced" inputs barely move the score.

• Time is the most powerful variable, and it isn't on the lab slip. A lifelong 10 mg/dL drop in LDL outperforms, per unit, a much larger drop started late in life. Early, modest, sustained change rivals aggressive, late pharmacology — which is an argument for habits, not just prescriptions.

• Lifestyle first, measurement always, escalation when the data calls for it. Every one of these guidelines front-loads lifestyle before drugs. The risk isn't the medication; it's the "set it and forget it" reflex of stacking treatments without ever rechecking whether they still earn their place.

3 Practical Takeaways

1. Start the fundamentals early, not perfectly. The biggest cardiovascular lever you have is cumulative — decades of decent sleep, real food, fiber, and movement compound like an index fund. You don't need an elite protocol. You need to start the boring habits sooner and keep them going. A modest change held for thirty years beats an aggressive one bolted on at fifty-five.

2. Know your numbers, including the ones you have to pay for. Get a lipid panel, know your blood pressure, and consider a one-time Lp(a) test and a ~$100 coronary calcium scan if you're at the age the guideline suggests. You can't manage what you don't measure, and a number on a scan can move you out of guessing and into a plan.

3. Treat every medication as a decision you revisit, not one you make once. If you start a drug, set a date to re-evaluate whether it's still working and still needed. "Set it and forget it" is how people end up on eight medications nobody has questioned in years. The goal is the smallest effective set, monitored honestly over time.